6. iv) Arrythrogenic right ventricular cardiomyopathy
a) genetic mutation in cardiomyocyte structure
v) LV non compaction
b) X-linked, AR, AD, mitochondrial, sporadic
www.dnbpediatrics.com
10. HOCM
It is a genetic disorder
Most common are mutations in genes encoding Cardiac B myosin
heavy chain (MYH7)Myosin binding protein C (MYBPC3)
AD pattern of inheritance
Other are PRKAG2 & LAMP2 α- galactosidase mutations
www.dnbpediatrics.com
11. PATHOGENESIS
Characterized by increased LV thickness in the absence of structural heart disease
or hypertension
Inter-ventricular septum is often disproportionately involved (IHSS) or (ASH).
In some patients intra-cavitary gradiant develops during systole.
This subaortic obstruction is caused by systolic anterior motion of mitral valve
against hypertrophied septum
Diastolic ventricular filling is impaired by abnormal stiffness of LV, which leads to LAH
and pulmo venous congestion, producing congestive symptoms
www.dnbpediatrics.com
12. a large volume of stroke volume (80%) is ejected during the early part of systole
when there is little or no obstruction, producing a sharp upstroke in the
arterial pulse- characteristic of HOCM
Because the obstruction of LVOT results from SAM of mitral valve against
hypertrophied septum, any influence that reduced LV systolic volume
(+ve inotropic agents, lowering of SVR. Low blood volume) will increase
obstruction and increase the murmur, while any influence that increases the
LV systolic volume (-ve inotropic agents, Leg raising, blood transfusion)
will decrease obstruction and decrease the murmur
www.dnbpediatrics.com
13. Clinical features
H/O : many patients asymptomatic
-50% cases present with heart murmur or detected
during family screening
-palpitation , chest pain, easy fatiguability,
-dyspnea, dizziness, syncope
-sudden death
www.dnbpediatrics.com
14. P/E
– over active pre-cordial impulse with a heave
abnormal PP
- Systolic ejection murmur in the aortic region
not associated with ejection click
- A sharp upstroke on arterial pulse
www.dnbpediatrics.com
15. ECG
– LVH, ST-T changes, abnormally deep Q waves
WPW syndrome in Danon and Pompe diasease
X-ray
- mild LVH with globular heart
- pulmo vascularity normal
www.dnbpediatrics.com
16. ECHO
Z Score of 2 or more relative to BSA is diagnostic
LV wall thickness Doppler helps in defining,
localising, quantifying the degree of myocardial
hypertrophy and also demonstrates degree of
LVOT and mitral insufficiency
Cardiac catheterization
Metabolic testing
Genetic testing
www.dnbpediatrics.com
17. MANAGEMENT
1) sternous activity prohibited and rest
2) B blockers like propranolol or atenolol or CCBs
like verapamil, useful in diminishing LVOT,
modifying ventricular hypertrophy and
improve ventricular filling.
- Though, risk of sudden death not decreased.
3) antiarrythmic treatment in patient with atrial or ventricular
arrythmias
www.dnbpediatrics.com
18. 4) patients with documented ventricular
arrythmias, strong family history or patients
with syncope – ICD
5) dual chamber pacing, alcohol ablation,
surgical septal myomectomy, MVR – limited success
6) first degree relatives should be screened every
3-5 years for patients under 12 years of age and
then yearly throughout the teenage and young adulthood
www.dnbpediatrics.com
19. PROGNOSIS
Children <1 year, with IEM or with some syndromes have poorer prognosis
Risk of sudden death is increased in patients with a History of cardiac arrest,
History of Vtach, Exercise hypotension, syncope>3 cm wall thickness,
F/H/O sudden death
www.dnbpediatrics.com
20. DCM
Most common form of cardiomyopathy
Most common cause of DCM is idiopathic
Among familial causes AD is most common
www.dnbpediatrics.com
21. PATHOLOGY AND PATHOPHYSIOLOGY
Weakening of systolic contraction
Dilatation of all 4 chambers
Dilatation of atria is in proportion to ventricles
(unlike RCM)
Intracavitary thrombus formation is common
in apical part of ventricles Pulmo& systemic emboli
On biopsy, myocyte hypertrophy and fibrosis
www.dnbpediatrics.com
22. CLINICAL FEATURES
history of – fatigue, weakness, dyspnea, orthopnea
P/E – s/o CHF (increased heart rate, crackles,
weak PP, distended neck veins, heapatomegaly)
Gallop rhythm, murmurs of MR or TR
www.dnbpediatrics.com
23. ECG
sinus tachycardia,
LVH & ST-T changes most common LAH,
RAH
Atrial or ventricular arrythmias
AV conduction disturbances
www.dnbpediatrics.com
24. x ray & echo
Cardiomegaly with or with out pulmonary edema
Echo – most important tool in diagnosis
pulmonary hypertension,
MR or other structural defects.
www.dnbpediatrics.com
26. MANAGEMENT
[1] medical treatment
Aimed at treating underlying heart failure
Diuretics, digoxin, ACEI, ARB
Bed rest and restriction of activity
Inotropic support and mechanical ventilation
www.dnbpediatrics.com
27. [2] B adrenergic blockade with carvedilol or metoprolol
Pediatric data not available
[3] ECMO, ventricular assist devices, cardiac transplantation
[4] specific antiarrythmic therapy and anticoagulation
www.dnbpediatrics.com
28. PROGNOSIS
1 and 5 year rates of death or need for transplantation in DCM
patients is 31% and 46%
Independent risk factors for death or need for transplant in DCM
patients are Older age, CCF Lower left ventricular functional
shortening zone
www.dnbpediatrics.com
29. RCM
<5 % of cases Incidence increases with age,
M<F Most common etiology is idiopathic
www.dnbpediatrics.com
30. PATHOGENESIS
Normal ventricular chamber diameter Normal ventricular wall
thickness Preserved systolic function Impaired ventricular filling
Normal size of ventricles with dilated atrias
www.dnbpediatrics.com
31. Clinical features
H/O : exercise intolerance, weakness, dyspnea, chest pain
P/E : jugular venous distention, gallop rhythm,
systolic murmur of AV valve regurgitation
ECG : bilateral AH, AV block
X-ray : cardiomegaly, pulmonary venous congestion
www.dnbpediatrics.com
32. ECHO : normal LV systolic function
diastolic dysfunction
bilateral AH with normal LV dimension
Cardiac catheterisation :
PApressure & RV & LV
EDP Increased
Endomyocardial biopsy
www.dnbpediatrics.com
33. MANAGEMENT
1)Treatment of CCF
2) CCB to increase diastolic compliance
3) anti-coagulants & anti-platelets to prevent thrombus
4) pacemaker for CHB5) cardiac transplantation
www.dnbpediatrics.com
35. SUMMARY OF CLINICAL CHARACTERISTICS OF CARDIOMYOPATHY
CLINICAL
FEATURES
HYPERTROPHIC DILATED RESTRICTIVE
CAUSE Inherited (AD in about
50%)
Sporadic(new mutation)
Pluricausal
(e.g.toxic metabolic,
infectious, alcohol,
doxorubicin
Myocardial fibrosis,
hypertrophy, or
unfiltration
(amyloid
hemochromatosis)
HEMO-
DYNAMIC
DYSFUNCTIO
N
Diastolic dysfunction (with
normal systolic function)
(abnormally stiff LV with
impaired ventricular filling
Systolic contractile
dysfunction
(decreased cardiac
output, decreased
stroke volume,
increased LVEDP)
Diastolic
dysfunction (rigid
ventricular walls
impede ventricular
filling
www.dnbpediatrics.com
36. CLINICAL FEATURES HYPERTROPHIC DILATED RESTRICTIVE
Echo (morphology) Thickened LV (and
occasionally RV) wall
-Small or normal LV chamber
dimensionsSupernormal LV
contractility HOCM and/or
ASH
Biventricular dilatation
(increased LVDD and LVSD)
-atrial enlargement in
proportion to ventricular
enlargement
-Decreased LV contractility
Apical thrombus(+/-)
Biatrial enlargement
-Normal LV and RV volume
Normal LV systolic function
until advanced stage Atrial
thrombus(+/-)
Doppler Reduced relaxation pattern Reduced relaxation pattern ‘reestrictive’ pattern
Treatment B-adrenoreceptor blockers
-calcium antogonists
(digitalis/catechols and
nitrates contraindicated)
- (diuretics may worsen the
symptoms)
Vasodilator therapy
-digitalis plus diuretics
B-adrenoreceptor
blockers(+/-)
-Anticoagulants
antiarrythmicsCardiac
transplantation
Diuretics
-Anticoagulants(+/-)-
corticosteroids(+/-)-
permanent pacemaker for
advanced heart blockCardiac
transplantation
www.dnbpediatrics.com
37. 4. LVNC
Left ventricular non compaction
affects all ages
Trabeculated or spongy appearing LV,
commonly a/w LVH or LV dilatation, and, at times systolic or diastolic dysfunction
ECG – LVH, ST-T changes or arrythmias
MRI – trabeculated LV myocardium,
characteristically within apex of left ventricle
Metabolic screen – especially in young patients TA2 gene mutation
www.dnbpediatrics.com
39. 5. ARVC
-Arrythmogenic right ventricular cardiomyopathy
-AD from most common
-AR forms a/w skin manifestations
-Characterized by dilated RV with fibrofatty
-infiltration of RV wall
-Global and regional right and left ventricular dysfunction and
-ventricular tachyarrythmias
-Syncope or sudden death can be the presentation
-Mx - antiarrythmics, defibrillation and Mx of HF, Cardiac transplantation
www.dnbpediatrics.com
40. [6] EFE
endocardial fibroelastosis
Incidence markedly decreased due to abolition of mumps virus inf by immunisation
Characterized by opaque, white, fibroelastic thickening on the endocardial surface
of the ventricle, which leads to systolic or diastolic dysfunction
Mx of HF & cardiac transplantation
www.dnbpediatrics.com
42. Definition and Etiology
Process characterized by inflammatory infiltrate of the
myocardium with necrosis and/or degeneration of adjacent
Myocytes, not typical of the ischemic damage associated with
coronary artery disease
Most cases from common viral infections and post-viral immune
-mediated responseCoxsackievirus A and B, echovirus, poliovirus,
PVB 19, HHV6Precursor of dilated cardiomyopathy
www.dnbpediatrics.com
46. Incidence
Often not recognized
Estimated annual incidence of 1/100.000
4 – 5% in young accident victims
12% in adolescents and young adults with sudden cardiac death
www.dnbpediatrics.com
47. Clinical features
H/O : URTI in older children or may have a sudden onset with
anorexia , vomiting, lethargy.
In new borns and infants signs of CHF like tachycardia, tachyapnea,
gallop rhythm, and arrythmia may be present.
A soft systolic heart murmur and supra ventricular or
ventricular ectopic beats may be present
www.dnbpediatrics.com
48. Laboratory Tests
Biomarkers (troponins, creatine kinase MB) occasionally elevated in childhood
(sensitivity 71%, specificity 86%)
Normal nonspecific markers of inflammation (CRP, leucocytes) do not exclude
acute myocardial inflammatory process
Utility of virus serology in patients with suspected myocarditis unproven –
costly and unreliable
• Detection of viral genome in urine or feces
www.dnbpediatrics.com
49. ECG
Abnormalities present in 93-100%, but low sensitivity
Sinus tachycardia
Nonspecific T-wave and ST-segment changes
ST-segment elevation
AV conduction delays
Atrial and ventricular arrhythmias
www.dnbpediatrics.com
55. Endomyocardial Biopsy
Is a Gold standard for diagnosis
Invasive, potential complications: pneumothorax, hemothorax, arrhythmias,
perforation, death
Enables identification of lymphocytic invasion and detection of involved virus
Poor sensitivity and specificity due to patchy myocardial inflammation
Substantial interobserver variation
www.dnbpediatrics.com
56. Histology/Dallas Criteria
Acute myocarditis: lymphocytic infiltrate with myocyte necrosis
Borderline myocarditis: inflammatory infiltrate without necrosis
Chronic myocardits/DCM with inflammation:
>14 inflammtory cells/mm2 in the myocardium
www.dnbpediatrics.com
57. Differential Diagnosis
Any disease with impairment of LV function
DCMA
LCAPA
Chronic tachycardia
Arteriovenous malformation
www.dnbpediatrics.com
58. Therapy I
Mainly supportive, no trials for specific heart failure therapy in biopsy-proven
myocarditis in adults and children
Monitoring of vital parameters
Bed rest initially, no physical activities for 3-6 months
Trat heart failure therapy with ACE inhibitors, AT1-antagonists ß-blockers,
diuretics and aldosterone antagonists according to current guidelines
Ventricular assist device <-> HTX
Therapy of tachyarrhythmias in adults - Life vest and AED
www.dnbpediatrics.com
59. Therapy II
In proven viremia: immunoglobulins 2 g/kg for 48 hours (Robinson JL 2005)
No immunosuppresive therapy – risk of enhanced virus replication and
blockade of endogenous interferons
Steroids only in biopsy-proven virus negative chroniC myocarditis (Frustacci A 2009)
Type-1 interferon (IFN-α, IFN-ß) beneficial in animal and human pilot studies
(Kühl U 2003, Schmaltz AA 1998)
www.dnbpediatrics.com
61. REFERENCES
TEXTBOOK OF PEDIATRIC CARDIOMYOPATHY – S. PARKS 6th edition
NELSON – 19th editionE-medicine.medscape.com
www.dnbpediatrics.com
www.criticalpediatrics.org